Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Social media

Riccardo De Giorgi

MD, DPhil, MRCPsych

Clinical Lecturer (post-CCT)

  • Clinical Lecturer (post-CCT)
  • Honorary Consultant in General Adult Psychiatry

Repurposing immuno-metabolic drugs in mental disorders

I am a post-CCT Clinical Lecturer at the University of Oxford Department of Psychiatry, and Honorary Consultant in General Adult Psychiatry at Oxford Health NHS Foundation Trust. In Oxford, I am a tutor in psychiatry and regularly teach medical students and trainees about the topics of research methodology and critical appraisal, psychopharmacology, and mood disorders. I am also Adjunct Professor at the University of Salento, Italy. I serve as Elected Council Member for the British Association of Psychopharmacology, EDI Ambassador at the NIHR Oxford Health Biomedical Research Centre, and BJPsych Journal Club Co-Coordinator for The BJPsych. I am Section/Associate Editor for the BJPsych, BJPsych Adv, BMJ Mental Health, and BMJ Connections Mental Health.

I enjoy the interplay between clinical practice and research, which drives me to be a determined clinician and inspires my academic interests. I am interested in neuropsychopharmacology and the evidence-based treatment of mental illness, especially mood disorders. There is increasing evidence that immunological and metabolic factors play a role in the pathophysiology of cognitive and mental disorders. Repurposing commonly used medical treatments (e.g., anti-inflammatory or metabolic interventions) may therefore benefit those patients who respond poorly to conventional treatments and who might be identifiable a priori through measurement of immunological and metabolic markers.

Currently, I am working on experimental medicine studies for the repurposing of drugs with immuno-metabolic activity (e.g., statins, GLP1-RAs) in mental disorders. This work is informed by collaborative projects in evidence synthesis and pharmacoepidemiology with several other research teams at the department. I look at early markers of response, such as neuropsychological changes, as well as  immuno-metabolic peripheral markers, to validate the use of these drugs in further clinical trials.